Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results from ...
Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback